The present antithrombotic drugs used to treat or prevent ischemic stroke have significant limitations: either they show only moderate efficacy (platelet inhibitors), or they significantly increase the risk for hemorrhages (thrombolytics, anticoagulants). Although most strokes are caused by thrombotic or embolic vessel occlusions, the pathophysiological role of platelets and coagulation is largely unclear. The introduction of novel transgenic mouse models and specific coagulation inhibitors facilitated a detailed analysis of molecular pathways mediating thrombus formation in models of acute ischemic stroke. Prevention of early platelet adhesion to the damaged vessel wall by blocking platelet surface receptors glycoprotein Ib alpha (GPIbα) or glycoprotein VI (GPVI) protects from stroke without provoking bleeding complications. In addition, downstream signaling of GPIbα and GPVI has a key role in platelet calcium homeostasis and activation. Finally, the intrinsic coagulation cascade, activated by coagulation factor XII (FXII), has only recently been identified as another important mediator of thrombosis in cerebrovascular disease, thereby disproving established concepts. This review summarizes the latest insights into the pathophysiology of thrombus formation in the ischemic brain. Potential clinical merits of novel platelet inhibitors and anticoagulants as powerful and safe tools to combat ischemic stroke are discussed.

Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1831–1840; doi:10.1038/jcbfm.2012.108; published online 18 July 2012

Keywords: coagulation; FXII; glycoprotein Ib; platelets; Stim; von Willebrand factor

Introduction

Recombinant tissue plasminogen activator (tPA) is the only approved medication in acute ischemic stroke. However, <20% of all stroke patients receive tPA (Weimar et al., 2006), a situation mainly owed to the narrow treatment time window of 4.5 hours. Another significant limitation of tPA is bleeding-related adverse events. Moreover, as time increases between symptom onset and treatment, the efficacy of tPA decreases (Lees et al., 2010). In the case of stroke prevention, the situation is not different. Platelet inhibitors (PIs) and anticoagulants are commonly used in (early) secondary prophylaxis, but often with limited efficacy (CAST, 1997; IST, 1997).

It is known for many years that during ischemic stroke platelets become locally activated and adhere to the cerebral endothelium, thereby promoting thrombus formation and subsequent thrombus growth (del Zoppo, 1998; Okada et al., 1994). Consequently, in some of the early experimental studies, the prototype of PIs, acetylsalicylic acid (ASA), was used in an attempt to salvage brain tissue by counteracting detrimental microvascular thrombosis. In rats, ASA was effective only after temporary, but not permanent, occlusion of the MCA (Berger et al., 2007). In mice, multiple applications of very high doses (6 × 40 mg/kg, which corresponds to roughly 19 g for humans) were needed to significantly reduce infarct volumes (Berger et al., 2004). Even then, no amelioration of functional deficits could be observed, whereas lower doses of ASA remained inefficient. The limited success of ASA in experimental stroke is in agreement with modest results in clinical trials for early (within the first 48
hours) secondary prophylaxis after ischemic stroke (CAST, 1997; IST, 1997). For example, one has to treat 100 stroke patients with ASA over 1 year to prevent one further stroke. Other platelet antagonists were also studied in experimental stroke. In baboons, Ticlopidin, an adenosine diphosphate receptor antagonist, which functions similarly to Clopidogrel by inhibiting the P2Y12 receptor on platelets, reduced the formation of microthrombi in the basal ganglia (del Zoppo, 1998). However, to achieve this effect, combination of Ticlopidin together with heparin was necessary, which complicates the interpretation of the results, that is, the differentiation of the pathways involved (platelet activation or thrombin activity). An important issue with the use of PIs in stroke is the risk of increased bleeding, reducing the benefit-hazard ratio (Hankey and Eikelboom, 2010).

The classic approach to inhibit coagulation-driven thrombus formation in models of acute ischemic stroke was to apply unfractionated or low-molecular-weight heparins (Libersan et al., 1998; Mary et al., 2001; Pratt et al., 1998; Yanaka et al., 1996a, 1996b). Although these enhancers of antithrombin III activity to some extent reduced infarct volumes and neurological deficits, the main drawback of unfractionated heparins was an increased risk of bleeding. For example, severe intracranial hemorrhages occurred in up to 25% of animals treated with heparin (Mary et al., 2001; Yanaka et al., 1996b). While some studies found a positive benefit-hazard ratio for low-molecular weight heparins such as enoxaparin (Mary et al., 2001), various studies in the clinical setting showed that the net benefit of heparins in general was outweighed by an increased risk of severe bleedings (Sandercock et al., 2008). Consequently, full-intensity parenteral anticoagulation with heparins either unfractionated or low-molecular weight is no longer recommended in the acute phase of cerebral ischemia (guidelines of the European Stroke Organisation (ESO): http://www.eso-stroke.org/pdf/ESO%20Guidelines_update_Jan_2009.pdf).

While new PIs (thromboxane receptor antagonists, phosphodiesterase inhibitors) and oral anticoagulants (direct thrombin inhibitors, factor Xa inhibitors) have recently been tested in humans or have even found their way into the clinical trials, this efficacy versus safety (bleeding risk) dilemma remains a burning issue (Bousser et al., 2011; Shinohara et al., 2010; Connolly et al., 2009). Hence, there is still a large unmet medical need for more effective and safer antithrombotics in stroke therapy. Platelets and coagulation factors increasingly gain attention as prime targets in stroke therapy. Yet, much remains unknown about the molecular pathways that initiate and perpetuate cerebral thrombus formation (Stoll et al., 2008; Kraft et al., 2011; Pham et al., 2012). This review summarizes novel pathophysiological insights into the role of platelets and coagulation in mouse models of stroke. Interestingly, while elucidating critical pathways of hemostasis and thrombosis in the brain these basic studies have led to the intriguing concept of ‘bleeding-free antithrombosis’ in stroke, which now awaits validation in future clinical trials.

Translational hurdles in the implementation of novel antithrombotics: it’s nice, but it’s (still) mice

In the search for new targets for improved antithrombotic treatment in ischemic stroke, it is important to recognize several translational caveats (reviewed in Braeuninger and Kleinschnitz (2009)). Indeed, efficient translation of novel experimental therapies into effective treatments for stroke patients has so far not been successful. One important consideration is that rodents are different from humans, with significant physiological, neuro-anatomical, and metabolic differences (Ishihara et al., 1998; Rowley et al., 2011). Although rodents classically are the first line of animals for experimental stroke studies, their use may bias results towards rodent physiology, hindering successful translation to humans. Also, when using genetically modified animals, for example, knockout or transgenic mice that have no counterpart in normal humans, one must take into account compensatory upregulation of alternative mechanisms that could alter cerebral vascular supply or tissue responses (Barone et al., 1993). Moreover, cerebral vasculature, hemostasis, and thrombosis may have specific characteristics that differ from established systemic concepts. For example, a particular phenomenon in ischemic stroke is infarct progression despite sustained early reperfusion of previously occluded blood vessels, a process known as ‘reperfusion injury’ (Nieswandt et al., 2011). On reperfusion of previously ischemic tissue, adherent platelets and leukocytes can obstruct microvessels and hinder efficient reperfusion, referred to as ‘no reflow’ (del Zoppo and Mabuchi, 2003). Collectively, it is clear that one has to be cautious when extrapolating promising findings in mouse models of stroke to human therapies. Preclinical follow-up studies in larger animal models, preferably gyrencephalic non-human primates, are therefore recommended as translational proof of concept before starting clinical trials (Cook et al., 2012).

The coagulation cascade as novel target in stroke therapy

The coagulation cascade consists of several serially connected serine proteases. Activation of the cascade leads to thrombin generation and ultimately fibrin formation, which stabilizes growing platelet thrombi. Whereas it is well established that the extrinsic coagulation pathway is triggered by tissue factor at sites of vascular damage, the physiological trigger for the intrinsic coagulation cascade remained elusive.
until recently. Indeed, recent elegant work showed that negatively charged ribonucleic acid or polyphosphates are potent activators of factor XII (FXII, Hageman factor) in vivo (Kannemeier et al., 2007; Müller et al., 2009). Interestingly, a new link between extracellular DNA traps and coagulation/thrombosis has recently been described, which also has a role in stroke (Fuchs et al., 2010; De Meyer et al., 2012b, in press).

Blocking specific components of the coagulation cascade, such as FIXa and FXa, resulted in hopeful findings. In a rat model of thromboembolic stroke, inhibition of FXa was shown to reduce infarct size and improve neurological outcome without increasing risk of bleeding (Wang et al., 2003). Similar findings were obtained when blocking FIX (Toomey et al., 2002). Another study in mice also showed that low doses of FIX inhibitor were protective in ischemic stroke without inducing intracranial hemorrhage, while higher doses resulted in more cerebral bleeding, similar to heparin and tPA (Choudhri et al., 1999). Larger studies are needed to further validate these central components of the coagulation cascade as safe and efficient targets in stroke therapy.

In recent years, also another factor, FXIIa, has gained increasing interest as an attractive candidate to prevent thrombus formation in the ischemic brain. Factor XII has long been thought to be physiologically irrelevant for thrombus formation as hereditary FXII deficiency is not linked with hemorrhagic diathesis, not even after trauma (Mackman, 2004). However, this paradigm had to be fundamentally revised in the last few years. The generation and characterization of FXII-deficient mice revealed that these animals built fewer and less stable thrombi after artificial vessel wall injury, but not at the cost of an increased rate of hemorrhages (Renne´ et al., 2005).

FXII-deficient mice have normal tail bleeding times, despite their increased activated partial thromboplastin time. Lack of FXIIa has also interesting consequences in experimental stroke: FXII/C0 mice subjected to transient middle cerebral artery occlusion (tMCAO) developed significantly smaller infarct volumes (by ~50%) and less severe neurological deficits compared with wild-type controls (Kleinschnitz et al., 2006). Histological analysis showed a profound reduction in microvascular thrombi in brain capillaries after stroke. Similarly, FXI/C0 mice were also protected from cerebral vessel-occluding fibrin formation and stroke after tMCAO, further showing the role of the intrinsic coagulation pathway in pathological clotting in stroke (Kleinschnitz et al., 2006). Important in terms of safety, intracranial hemorrhage did not occur in the absence of FXII activity as shown by blood-sensitive magnetic resonance imaging (MRI).

Findings obtained from transgenic mouse models are interesting from a mechanistic perspective, but do not represent the clinical situation. If one wants to treat a patient, a pharmacological inhibitor is needed. A very selective inhibitor of FXIIa is recombinant protein rHA-Infestin-4 (CSL Behring GmbH, Marburg, Germany), a Kazal-type serine protease inhibitor originally isolated from the gut of the sanguivorous kissing bug Triatoma infestans (upper panel) that inhibits FXIIa with a high level of specificity. Pretreatment of mice with rHA-Infestin-4 dramatically reduced infarct volumes on day 1 after 60 minutes of tMCAO, as shown by infarct volumetry from 2,3,4-triphenyltetrazoliumchloride (TTC)-stained brain slices (lower panels). The ischemic areas appear in white. Importantly, no signs of increased intracranial bleeding were found on day 1 after rHA-Infestin-4 treatment (adapted from Hagedorn et al., 2010). Ctrl, Control; Inf-4, rHA-Infestin-4; FXIIa, factor IIa.

Figure 1 rHA-Infestin-4 protects from ischemic stroke in mice. rHA-Infestin-4 is a Kazal-type serine protease inhibitor originally isolated from the gut of the sanguivorous kissing bug Triatoma infestans (upper panel) that inhibits FXIIa with a high level of specificity. Pretreatment of mice with rHA-Infestin-4 dramatically reduced infarct volumes on day 1 after 60 minutes of tMCAO, as shown by infarct volumetry from 2,3,4-triphenyltetrazoliumchloride (TTC)-stained brain slices (lower panels). The ischemic areas appear in white. Importantly, no signs of increased intracranial bleeding were found on day 1 after rHA-Infestin-4 treatment (adapted from Hagedorn et al., 2010). Ctrl, Control; Inf-4, rHA-Infestin-4; FXIIa, factor IIa.

Findings obtained from transgenic mouse models are interesting from a mechanistic perspective, but do not represent the clinical situation. If one wants to treat a patient, a pharmacological inhibitor is needed. A very selective inhibitor of FXIIa is
Despite promising preclinical data, the relevance of FXII in the pathophysiology of human stroke cannot be judged so far. Interestingly, the index patient John Hageman died from pulmonary embolism (albeit after a preceding accident) and since then FXII deficiency was for a long time assumed to act prothrombotic (Gailani and Renné, 2007). Overall, evidence from epidemiological or clinical studies is conflicting and difficult to interpret: FXIIa levels above the 90th percentile were associated with a 2.1-fold increased probability of stroke in younger women taking oral contraceptives (Siegertink et al, 2010), and 21 patients with severe FXII deficiency developed no arterio-embolic events within a 15-year period (Girolami et al, 2005). In contrast, a case-control study showed that low FXIIa levels in middle-aged men were associated with an increased risk for coronary artery disease and stroke (Govers-Riemslag et al, 2007). Finally, deficiency of FXI, the prime substrate of FXIIa, protected from stroke but not myocardial infarction in a Jewish population (Salomon et al, 2008). Available evidence points towards a dose-dependent, maybe even a U-shaped correlation between FXIIa levels and the likelihood of thrombosis. However, prospective epidemiological studies that are adequately powered are difficult to realize, as people with FXII deficiency are ‘phenotypically healthy’ except for a prolonged activated partial thromboplastin time.

The quest for novel inhibitors of platelet function

The increasing availability of transgenic mouse strains and specific blocking agents paved the way for identification of novel molecules that control platelet function and activation (Stegner and Nieswandt, 2010; Stoll et al, 2008). Use of these tools in experimental stroke settings has much improved our understanding of detrimental thrombus formation in the ischemic brain. Classically, arterial thrombus formation is considered a multistep process, involving platelet rolling over vascular lesions, followed by firm adhesion, platelet activation, and eventually stable platelet aggregate formation (Figure 2). Under conditions of high shear stress (>800/s, found in normal arteriolar circulation or stenosed arteries), platelets need to be slowed down to allow firm arrest at sites of vascular injury. This is accomplished by the reversible interaction of the platelet-specific glycoprotein (GP) Ib-V–IX receptor complex with immobilized von Willebrand factor (VWF) present in the subendothelium, or immobilized from plasma onto exposed collagen, or present on endothelium as VWF strings after release by activated endothelial cells (De Meyer et al, 2012a), resulting in the so-called ‘tethering’ or ‘rolling’ of platelets in the direction of the blood flow. This permits platelets to establish more stable interactions that lead to definitive arrest, such as binding to collagen with their collagen receptors. Among the two main collagen receptors on platelets, GPVI and GPIIa/IIa, the former is considered the most functionally relevant, eliciting strong activation signals on engagement (Nieswandt and Watson, 2003; Broos et al, 2011). Platelet activation finally results in a conformational change of the GPIIb/IIIa receptor. Activated GPIIb/IIIa then promotes platelet aggregation by binding fibrinogen (and to a lesser extent VWF), which will act as a substrate for recruitment of additional platelets.

In the last few years, extensive effort has been made to investigate whether this classical view of arterial thrombus formation is also valid in (ischemic) brain vasculature. These studies have revealed interesting insights that could lead to new treatment strategies in stroke management.

Blocking the GPIb–VWF axis

Because of its absolute importance for platelet adhesion under high shear conditions, the GPIb–VWF axis has become an attractive target for the development of new antithrombotic agents. During the last decade,
the antithrombotic efficacy of GPIb–VWF inhibition has been well established using various experimental arterial thrombosis models (reviewed in De Meyer et al. [2012a]). However, the role of GPIb–VWF during cerebral ischemia remained elusive until recent studies showed a clear involvement of the GPIb–VWF axis in stroke development. First, we showed in mice that injection of early platelet adhesion by anti-GP Ibα Fab dramatically reduced stroke volumes and functional deficits 1 day after 60 minutes of tMCAO (Kleinschnitz et al., 2007). Importantly, both prophylactic administration of anti-GP Ibα Fab (before tMCAO) and therapeutic application (1 hour after stroke induction) were equally efficient and the beneficial effect lasted for days. Although mice treated with anti-GP Ibα Fab had prolonged tail bleeding times, serial MRI could exclude a higher frequency of intracranial hemorrhages (Kleinschnitz et al., 2007). This study showed that GPIb is indeed a major player in arterial thrombus formation in ischemic or reperfused brain, but is not necessary for the prevention of bleeding complications after brain ischemia/reperfusion injury. This concept was confirmed using mice expressing GPIbα, in which the extracellular domain was replaced by that of the human interleukin-4 receptor (GPIbα-TG). These mice also developed smaller infarctions, had better neurological outcomes and did not develop intracranial bleeding after 60 minutes of tMCAO (De Meyer et al., 2011). These results also challenge the widespread concept of a tight correlation between bleeding time and the probability of a hemorrhage (Rodgers and Levin, 1990; Stoll et al., 2008). Further demonstrating the beneficial effect of GP Ibα blockade, we showed via perfusion-weighted continuous arterial spin-labeling imaging that inhibition of GP Ibα increases cortical reperfusion after tMCAO (Pham et al., 2011).

As described above, binding of GP Ibα to VWF is essential for platelet adhesion. von Willebrand factor is a multimeric GP produced in megakaryocytes and endothelial cells only. Lack of functional VWF results in the common bleeding disorder von Willebrand disease (De Meyer et al., 2009). The crucial role of VWF in cerebral ischemia/reperfusion injury was revealed by two independent studies showing that VWF-deficient mice develop significantly smaller strokes compared with control mice (Kleinschnitz et al., 2009; Zhao et al., 2009). This protection was reversed when VWF-deficient mice were reconstituted with VWF via hydrodynamic gene transfer (Kleinschnitz et al., 2009; De Meyer et al., 2010). To gain more insight into the specific roles of the different VWF domains, we transferred different VWF mutants into VWF-deficient mice. These experiments showed that binding of VWF to collagen and GPIbα, but not to GPIbα/IIa, are mandatory steps in stroke development (De Meyer et al., 2010). Again, mice lacking VWF showed no increased susceptibility for intracranial hemorrhages after 1-hour tMCAO. Together, these results underline the importance of the GPIb–VWF axis in pathological thrombus formation during cerebral ischemia/reperfusion.

Recently, population-based studies have shown that enhanced VWF serum levels are an independent risk factor for ischemic stroke (Bongers et al., 2006; Wieberdink et al., 2010). Moreover, different VWF polymorphisms associated with an increased risk of stroke have been identified (Dai et al., 2001; van Schie et al., 2011). Not all of these are associated with higher VWF levels, suggesting that other mechanisms, such as increased VWF activity, could contribute to the risk of stroke as well.

Activity of VWF is regulated by an enzyme called ‘a disintegrin-like and metalloprotease with thrombospondin repeats 13’ (ADAMTS13). Activity of VWF is strongly correlated with multimer size, and ultralarge VWF multimers can even spontaneously form microthrombi. To prevent spontaneous thrombus formation, ultralarge VWF is cleaved into smaller, less reactive molecules by ADAMTS13. Lack of ADAMTS13 activity results in thrombotic thrombocytopenic purpura (Moscovitz syndrome), characterized by microthrombi that occlude the vascular beds of many organs, including the brain (Lindblom et al., 2009; Sevy et al., 2011). Interestingly, ADAMTS13-deficient mice develop significantly larger strokes than wild-type mice (Fujikawa et al., 2010; Zhao et al., 2009), further confirming the notion of VWF as a central player in thrombus formation in cerebral vessels after stroke. Conversely, treatment of wild-type mice with ADAMTS13 led to smaller infarcts, without sensitizing to brain hemorrhage (Zhao et al., 2009). This indicates that, next to inhibiting the GPIb–VWF interaction, also cleavage of VWF itself may become a potential new strategy in stroke treatment.

Despite the promising results in experimental stroke, the translational impact of GPIb–VWF inhibition (or ADAMTS13 treatment) is still limited. Broader time windows after the onset of stroke and other stroke models than the mouse tMCAO model have to be tested to fully proof the translational character of these findings. Nevertheless, a relevance of platelet GPIb for human stroke might indeed exist. Several Gp1bα gene polymorphisms that cause an enhanced interaction between GPIbα and VWF are associated with an increased risk of stroke (Baker et al., 2001; Reiner et al., 2000).

**GPVI blockade**

Platelet GPVI is crucial for stable platelet adhesion on exposed collagen because it induces strong signaling for platelet activation (Figure 2). Glycoprotein VI is a type 1 transmembrane receptor from the immunoglobulin superfamily and is expressed exclusively on platelets (Nieswandt and Watson, 2003). Blockade of GPVI with specific antibodies very effectively prevented thrombus formation in different *in vitro* and *ex vivo* models of experimental thrombosis (Grüner et al., 2003; Massberg et al., 2003;...
Platelet signaling

The promising results regarding GPIIb and GPVI inhibition entailed follow-up studies on pathways downstream of these receptors. One fundamental step in platelet activation is the rapid rise of intracellular calcium concentration (Feske, 2007; Grosse et al., 2007). Following binding of VWF, collagen, or adenosine diphosphate to their respective receptors on the platelet surface (see above), phospholipase C hydrolyzes phosphatidylinositol-4,5-biphosphate to form inositol-1,4,5-trisphosphate and diacylglycerol. Inositol-1,4,5-trisphosphate then triggers the release of Ca\textsuperscript{2+} from the endoplasmic reticulum. The intracellular Ca\textsuperscript{2+} sensor stromal interaction molecule 1 (Stim 1) is an important activator of calcium release-activated calcium channel protein 1, a calcium selective ion channel in the plasma membrane encoded by the Orai1 gene, that mediates Ca\textsuperscript{2+} influx from the extracellular space (Figure 3). Stromal interaction molecule 1–Orai channels have recently been identified as the underlying molecular mechanism of store-operated calcium entry in platelets (Varga-Szabo et al., 2009). Interestingly, mice lacking Stim1 or Orai1 in platelets built less thrombi and were protected from ischemic stroke (Braun et al., 2009; Elvers et al., 2010; Varga-Szabo et al., 2008). This key role of Stim and Orai was not previously known and the development of specific inhibitors could enable a novel therapeutic approach.

Another interesting molecule in platelets is phospholipase D1, which acts downstream of GPIIb. Platelets from phospholipase D1-deficient mice have deficits in GPIIb-dependent aggregation. Importantly, formation and stabilization of platelet thrombi required phospholipase D1 only under high shear conditions, but not under low or intermediate shear as in the venous system. The fact that Pld1\textsuperscript{-/-} mice were protected against focal cerebral ischemia further underlines the involvement of GPIIb interactions and downstream signaling via phospholipase D1 in ischemic stroke (Elvers et al., 2010).

GPIIb/IIIa blockade

The GPIIb/IIIa pathway is crucial for mediating irreversible platelet aggregation and subsequent thrombus growth (Figure 2). Consequently, pharmacological inhibition of this final pathway of platelet activation has been a favored antithrombotic strategy (Armstrong and Peter, 2012). Surprisingly however, application of anti-GPIIb/IIIa Fab did not alter stroke size or functional outcome in the murine tMCAO model (Kleinschnitz et al., 2007). Instead, the therapy resulted in a massive rise in intracerebral hemorrhages and mortality. Similarly, reconstituting VWF\textsuperscript{-/-} mice with VWF unable to bind to GPIIIa/IIIb did not protect from stroke in the same model (De Meyer et al., 2010). Considering the beneficial effects when blocking early platelet adhesion through GPIIb or GPVI inhibition, these results at a first glance appear counterintuitive. However, it is known that GPIIb is able to bind to other molecules besides VWF, such as P-Selectin on endothelial cells and Mac-1 on leukocytes (Berndt et al., 2001). Therefore, inhibition of, for example, GPIIb seems, in contrast to GPIIa/IIIb blockade, to positively influence several mechanisms of microvascular dysfunction (thrombosis, inflammation), and thus to provide a broader protection from neuronal damage (Stoll et al., 2010).

Other studies using different GPIIb/IIIa antagonists reported an improved functional outcome after experimental stroke, but these were also accompanied by a dose-dependent increase in intracranial bleeding (Choudhri et al., 1999). Similarly, bleeding problems were also observed during the AbEST-II
phase III clinical trial, studying the efficacy of the GPIIb/IIIa antagonist Abciximab in patients with acute ischemic stroke (Adams et al., 2008). The study had to be stopped prematurely due to a significant increase in bleeding complications and a lack of efficacy in the treated group. In the Safety of Tirofiban in Acute Ischemic Stroke (SaTIS) trial, tirofiban reduced overall 6-month mortality, but failed to improve neurological outcome and disability (Siebler et al., 2011). Another trial compared the efficacy of tirofiban and ASA in a 6 hours time window after stroke, but did not find superiority of tirofiban over ASA in improving short-term neurological course and reducing long-term disability (Torgano et al., 2010). Thus, GPIIb/IIIa inhibitors seem to have a low-therapeutic range, at least in ischemic stroke. If GPIIb/IIIa antagonists fall below the lower therapeutic margin, activation of platelets can result; if they go above the upper therapeutic margin, the risk for bleeding complications rises (Bhatt and Topol, 2003). A better understanding of the molecular pathways of GPIIb/IIIa during stroke and of the pharmacology of GPIIb/IIIa antagonists will be necessary for substantial improvement in this regard.

Antithrombotic therapy without bleeding: a realistic option in stroke therapy?

An important characteristic of an ideal antithrombotic drug is that it should not increase the risk of bleeding. This is particularly important in the brain where a small intracranial hemorrhage already can have devastating consequences. As described above, several new experimental strategies seem promising in this regard, including inhibition of factors IX, XI and XII, GPIb–VWF, and GPVI. Interestingly, in several models of arterial thrombosis, inhibition of the collagen–VWF–GPIb axis showed a broader therapeutic window free of bleeding events when compared with GPIIb/IIIa blockers (reviewed in De Meyer et al. (2006)). Whether this holds true for stroke remains to be established. Direct comparisons of novel experimental stroke therapies are still lacking, but will be necessary to find the most promising candidates. In this respect, it will be interesting to see whether targeting molecules of which deficiency is not associated with a severe human bleeding diathesis (e.g., FXII, GPVI) will be safer in terms of hemorrhagic risk than inhibiting factors that are essential for normal hemostasis (e.g., FIX, VWF, GPIb). For example, inhibition of GPVI seemed to be safer and more effective than inhibition of GPIIb/IIIa (Kleinschnitz et al., 2006). These comparisons in various models of stroke will also help to segregate the various strategies in relation to prevention or treatment of stroke (primary prevention, thrombolysis, secondary prevention, and so on).

Nevertheless, it should be stressed that absence of bleeding in experimental models of stroke will not necessarily mean bleeding-free protocols in humans. Similarly, there is little evidence that experimental bleeding times in animals closely reflect hemorrhagic events in humans. Thus, while initial experimental stroke studies may indicate a beneficial effect on bleeding risk, close computed tomography or MRI monitoring of potential hemorrhagic transformation in further translational studies are required to show reduced bleeding risks in patients. Finally, absence of intracranial hemorrhage does not exclude that hemostasis could be impaired in other vascular beds, as it has been suggested that the hemostatic system in the central nervous system is different from that in other organ systems (Rosenberg and Aird, 1999).

Summary and perspective

During recent years, an increasing amount of experimental stroke studies has greatly improved our understanding of various coagulation and/or thrombotic pathways that mediate stroke progression. Although we should be aware of translational pitfalls, use of these animal models has revealed several novel targets that potentially could improve stroke therapy and/or prevention. Such innovations are badly needed considering that a plethora of attempts to implement novel thrombolytics or platelet inhibitors have spectacularly failed in the past. In terms of translation to human therapy, it is encouraging that several of these new compounds are currently enrolled in late preclinical and even clinical studies. Examples are rHA-Infestin-4 (Esmon, 2010; Jackson, 2011), nanobodies or aptamers inhibiting GPIb–VWF (reviewed in De Meyer et al. (2012a)) or humanized anti-VWF antibodies that inhibit VWF-mediated platelet adhesion (Fontayne et al., 2006; De Meyer et al., 2006; Staelens et al., 2006). Larger translational studies and proof-of-principle clinical trials are now needed to further validate these novel approaches in stroke management, either confirming their safety and efficacy or showing them falling victim to the frequently cited ‘translational roadblock’ in stroke research.

Acknowledgements

SFDM is a postdoctoral fellow of the Fonds voor Wetenschappelijk Onderzoek Vlaanderen.

Disclosure/conflict of interest

CK received financial support from CSL Behring GmbH, Marburg, Germany, for studying novel FXIIa inhibitors in ischemic stroke. PK and SFDM have no conflicts of interests.
Author contributions: All authors have read and approved the final manuscript. PK, SFDM, and CK wrote the paper.

References

Adams Jr HP, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W, AbESTT-II Investigators (2008) Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 39:87–99

Al-Tamimi M, Gardiner EE, Thom JY, Shen Y, Cooper MN, Hankey GJ, Berndt MC, Baker RI, Andrews RK (2011) Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke 42:498–500

Armstrong PC, Peter K (2012) GPIIb/IIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost 107:808–14

Baker RI, Eikelboom J, Loffthouse E, Staples N, Afshar-Al-Tamimi M, Gardiner EE, Thom JY, Shen Y, Cooper MN, Hankey GJ, Berndt MC, Baker RI, Andrews RK (2011) Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke 42:498–500

Armstrong PC, Peter K (2012) GPIIb/IIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost 107:808–14

Baker RI, Eikelboom J, Loffthouse E, Staples N, Afshar-Al-Tamimi M, Gardiner EE, Thom JY, Shen Y, Cooper MN, Hankey GJ, Berndt MC, Baker RI, Andrews RK (2011) Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke 42:498–500

Barone FC, Knudsens NJ, Nelson AH, Feuerstein GZ, Willette RN (1993) Mouse strain differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy. J Cereb Blood Flow Metab 13:683–92

Berger C, Stauder A, Xia F, Sommer C (2007) Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia. Exp Neurol 210:543–8

Berger C, Xia F, Schabitz WR, Schwab S, Grau A (2004) Essential for pathological thrombus formation.

Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Bhatt DL, Topol EJ (2003) Scientific and therapeutic problems.

Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H (2011) Platelets at work in primary hemostasis. Blood Rev 25:155–67

CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 349:1641–9

Choudhri TF, Hoh BL, Prestigiacomo CJ, Huang J, Kim LJ, Schmidt AM, Kiesel W, Connolly Jr ES, Pinsky DJ (1999) Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med 190:91–9

Connelly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Dzur R, Lewis BS, Darius H, Dieners H, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–51

Cook DJ, Teves L, Tymianski M (2012) Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 483:213–7

Dai K, Gao W, Ruan C (2001) The Sma I polymorphism in the von Willebrand factor gene associated with acute ischemic stroke. Thromb Res 104:389–95

Del Zoppo GJ (1998) The role of platelets in ischemic stroke. Neurology 51:S9–14

Del Zoppo GJ, Mabuchi T (2003) Cerebral microvesSEL responses to focal ischemia. J Cereb Blood Flow Metab 23:879–94

De Meyer SF, Deckhyn H, Vanhoorelbeke K (2009) Von Willebrand factor to the rescue. Blood 113:5049–57

De Meyer SF, Schwarz T, Deckhyn H, Denis CV, Nieswandt B, Stoll G, Vanhoorelbeke K, Kleinschinz C (2010) Binding of von Willebrand factor to collagen and glycoprotein Ib/IIa, contribute to ischemic stroke in mice—brief report. Arterioscler Thromb Vasc Biol 30:1949–51

De Meyer SF, Schwarz T, Schatzberg D, Wagner DD (2011) Platelet glycoprotein Ib is an important mediator of ischemic stroke in mice. Exp Transl Stroke Med 3:9

De Meyer SF, Stoll G, Wagner DD, Kleinschinz C (2012a) Von Willebrand factor: an emerging target in stroke therapy. Stroke 43:599–606

De Meyer SF, Suidan GL, Fuchs TA, Monestier M, Wagner DD (2012b) Extracellular chromatin is an important mediator of ischemic stroke in mice. ATVB, in press

De Meyer SF, Vanhoorelbeke K, Ulrichs H, Staelens S, Feys HB, Salles I, Fontayne A, Deckman H (2006) Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs. Cardiovasc Hematol Drug Disc Targets 6:191–207

Elvers M, Stegner D, Hagedorn I, Kleinschinz C, Braun A, Kuipers ME, Boels M, Chen Q, Heemsiek JW, Stoll G, Frohman MA, Nieswandt B (2010) Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1. Sci Signal 3:ra1

Esmen CT (2010) Far from the heart: counteracting coagulation. Nat Med 16:759–60

Feske S (2007) Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 7:690–702

Fontayne A, Vanhoorelbeke K, Pareyn I, Van Rompaey I, Meiring M, Lamprecht S, Rood J, Desmet J, Deckman H (2006) Rational humanization of the powerful antithrombotic anti-GPIIb/IIIa antibody: 6B4. Thromb Haemost 96:671–84

Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers Jr DD, Wrobleski SK, Wakefield TW, Hartwig H, Wagner DD (2010) Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 107:15880–5

Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1831–1840
Renne T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B (2005) Defective thrombus formation in mice lacking coagulation factor XII. *J Exp Med* 202:271–81.

Rodgers RP, Levin J (1990) A critical reappraisal of the bleeding time. *Semin Thromb Hemost* 16:1–20.

Rosenberg RD, Aird WC (1999) Vascular-bed—specific hemostasis and hypercoagulable states. *N Engl J Med* 340:1555–64.

Rowley JW, Oler AJ, Tolley ND, Hunter BN, Low EN, Nix DA, Yost CC, Zimmerman GA, Weyrich AS (2011) Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. *Blood* 118:e101–11.

Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U (2008) Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. *Blood* 111:4113–7.

Sandercock PA, Counsell C, Kamal AK (2008) Anticogulants for acute ischaemic stroke. *Cochrane Database Syst Rev* 4:CD000024.

Sevy A, Doche E, Squarciioni C, Poullin P, Serratrice J, Stegner D, Nieswandt B (2010) Platelet receptor signaling in thrombus formation. *J Clin Apher* 26:152–5.

Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tushima M, Koretsune Y, Sawada T, Hamada C (2010) Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. *Lancet Neurol* 9:599–608.

Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, Röther J, Witte OW, Hamann G, Junghans U, Villringer A, Fiebach JB (2011) Safety of tissue plasminogen activator heralding an acquired thrombotic thrombocytopenic purpura. *J Clin Apher* 26:152–5.

Stoll G, Kleinschnitz C, Nieswandt B (2008) Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. *Blood* 112:3555–62.

Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC (2002) Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. *Stroke* 33:578–85.

Torgano G, Zecca B, Monzani V, Maestroni A, Rossi P, Cazzaniga M, Manganaro D, Boiti C, Zilio E, Borutti G, Falaschi F, Mandelli C (2010) Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. *Cerebrovasc Dis* 29:275–81.

van Schie MC, de Maat MP, Isaacs A, van Duijn CM, Deckers JW, Dippel DW, Leebeek FW (2011) Variation in the von Willebrand factor gene is associated with WVF levels and with the risk of cardiovascular disease. *Blood* 117:1393–9.

Varga-Szabo D, Braun A, Kleinschnitz C, Bender M, Pleines I, Pham M, Renné T, Stoll G, Nieswandt B (2008) The calcium sensor STIM1 is an essential mediator of arterial thrombosis and ischemic brain infarction. *J Exp Med* 205:1583–91.

Varga-Szabo D, Braun A, Nieswandt B (2009) Calcium signaling in platelets. *J Thromb Haemost* 7:1057–66.

Wang X, Xu L, Wang H, Grzanna R, Zhan X, Knabb RM, Luetgten JM, Bozarth TA, Galembo RA, Wong PC, Bernard R, Vargas H, Chopp M, Friedman SM, Feuerstein GZ (2003) Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats. *Stroke* 34:468–74.

Weimar C, Kraywinkel K, Maschke M, Diener HC (2006) Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator. *Cerebrovasc Dis* 22:429–31.

Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, Leebeek FW, Breteler MM (2010) High von Willebrand factor levels increase the risk of stroke. The Rotterdam study. *Stroke* 41:2151–6.

Yanaka K, Spellman SR, McCarthy JB, Lown WC, Camarata PJ (1996b) Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia, II: dose-response effect and the therapeutic window. *J Neurosurg* 85:1108–12.

Yanaka K, Spellman SR, McCarthy JB, Oegema Jr TR, Low WC, Camarata PJ (1996a) Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia, I: protective mechanism. *J Neurosurg* 85:1102–7.

Zhao BQ, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M (2009) von Willebrand factor–cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. *Blood* 114:3329–34.

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/